Van Morris

33PUBLICATIONS

243CO-AUTHORS

Cancer geneticsCancer therapy (excl. chemotherapy and radiation therapy)ChemotherapyPredictive and prognostic markersMolecular targets

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (33)

Sort by Publication Date:

|May 08, 2026

Reprogramming of Cellular Plasticity via ETS and MYC Core-regulatory Circuits During Response to MAPK Inhibition in BRAF-mutant Colorectal Cancer.

|Jan 07, 2026

NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal.

Van K Morris, Kristen K Ciombor, Lianchun Xiao

|Sep 02, 2025

De-escalating local therapies without compromising outcomes: lessons from the COLLISION trial.

Jessica Albuquerque, Noreen S Siddiqi, Van K Morris

|Jul 16, 2025

Phase II Trial of TAS-102 in Colorectal Cancer Patients With Circulating Tumor DNA-Defined Minimal Residual Disease After Adjuvant Therapy: INTERCEPT-TT.

Andrew J Pellatt, Alisha Bent, Nicholas Hornstein

|Jul 11, 2025

Phase I Clinical Trial of the Bifunctional EGFR/TGF-β Fusion Protein Ficerafusp Alfa (BCA101) Alone and in Combination with Pembrolizumab for Advanced Solid Tumors.

Alberto Hernando-Calvo, Richard D Carvajal, Paul K Paik

|May 15, 2025

Long-Term Efficacy of Pembrolizumab and the Clinical Utility of ctDNA in Locally Advanced dMMR/MSI-H Solid Tumors.

Michael LaPelusa, Wei Qiao, Bryan Iorgulescu

Pageof 6

Frequent Collaborators

11 joint publications

Scott Kopetz

Michael Overman

Cathy Eng

Arvind N Dasari

Christine Parseghian

Kanwal Raghav

Jason Willis

Benny Johnson

Erin B Kennedy

Dipen Maru

Frequent Collaborators

11 joint publications

Scott Kopetz

7 joint publications

Michael Overman

7 joint publications

Cathy Eng

6 joint publications

Arvind N Dasari